People: argenx SE (ARGX.OQ)
24 Jan 2020
Dr. Pamela M. Klein serves as Non-Executive Independent Director of argenx SE since April 28, 2016. Dr. Klein is a principal and founder of PMK BioResearch, which offers strategic consulting in oncology drug development to corporate boards, management teams and the investment community, a position she has held since 2008. She currently serves as a member of various scientific advisor boards. Previously, Dr. Klein spent seven years at the National Cancer Institute as Research Director of the NCI-Navy Breast Center, after which she joined Genentech and was VP, Development until 2001. She served as Chief Medical Officer for Intellikine which was acquired by Takeda. She was previously Vice President, Development for Genentech. Dr. Klein holds a Bachelor’s degree in biology from California State University and an M. D. from Stritch School of Medicine, Loyola University, Chicago and is trained in internal medicine and medical oncology. She is Member of the Research and Development Committee of the Company.
|Total Annual Compensation, EUR||487,400|
|Restricted Stock Award, EUR||--|
|Long-Term Incentive Plans, EUR||--|
|All Other, EUR||--|
|Fiscal Year Total, EUR||487,400|